Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05853835 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A Phase 1 study, sponsored by LAPIX Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT05853835 is a Phase 1 study that has completed, run by LAPIX Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT05853835, a Phase 1 study, has completed, sponsored by LAPIX Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
Interventions
- DRUG LPX-TI641
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2024-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05853835
The ClinicalTrials.gov registry entry for NCT05853835 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LAPIX Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LPX-TI641 is the first listed.
NCT05853835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05853835 about?
NCT05853835 is a clinical study titled "First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641". A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
What is the current status of trial NCT05853835?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-10-30. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT05853835?
The interventions under investigation include: LPX-TI641 (DRUG).
Who is sponsoring clinical trial NCT05853835?
This trial is sponsored by LAPIX Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.